Trials / Completed
CompletedNCT00725582
Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
The Effects of IMA-026 on Allergen-Induced Airway Responses and Airway Inflammation in Subjects With Mild Atopic Asthma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given as 2 injections under the skin 1 week apart at 2 mg/kg each dose. The study will include a screening period and a treatment period which includes doses on day 1 and day 8.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMA-026 | |
| OTHER | Placebo |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2008-07-30
- Last updated
- 2009-06-02
Source: ClinicalTrials.gov record NCT00725582. Inclusion in this directory is not an endorsement.